ReviewVirology journal2025
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.
Review in Virology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Alterations in macular microvasculature in chronic hepatitis B patients measured by optical coherence tomography angiography.Quantitative imaging in medicine and surgery · 2026Article
- National trends in acute viral hepatitis in China from 1990-2023: An analysis of the Global Burden of Disease 2023 update.Chinese medical journal · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis poses a considerable risk to public health. Among the five hepatitis viruses, hepatitis B, C, and D virus are of particular concern due to their high rates of chronic infection and significant global disease burden. The World Health Organization's Global Health Sector Strategy, introduced in 2016, seeks to eradicate viral hepatitis as a public health issue by 2030, aiming for a 90% decrease in new infections and a 65% drop in fatality rates. Currently, there are several preventive and therapeutic interventions that can effectively halt the progression of the disease to an advanced stage. Nevertheless, forthcoming therapies must prioritize safety and effectively manage viral progression in a timely manner. Enhanced understanding of the molecular and immunological mechanisms underlying hepatitis viruses' infections would facilitate the formulation of effective treatment strategies. This review summarizes the pathogenesis of these viruses, explores prevention strategies such as vaccination and public health measures, and discusses current and emerging treatments. Emphasizing ongoing global efforts and future directions, this review highlights the critical need for sustained international collaboration to achieve the eradication of chronic viral hepatitis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.